scholarly journals Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

2013 ◽  
Vol 58 (1) ◽  
pp. e1-e34 ◽  
Author(s):  
Judith A. Aberg ◽  
Joel E. Gallant ◽  
Khalil G. Ghanem ◽  
Patricia Emmanuel ◽  
Barry S. Zingman ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Hiv Infection ◽  
Healthcare Providers ◽  
Health Problems ◽  
Antiretroviral Drugs ◽  
New Information ◽  
Immunodeficiency Virus ◽  
Care Guidelines ◽  
Evidence Based Guidelines ◽  
Specific Health

Abstract Evidence-based guidelines for the management of persons infected with human immunodeficiency virus (HIV) were prepared by an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America. These updated guidelines replace those published in 2009. The guidelines are intended for use by healthcare providers who care for HIV-infected patients. Since 2009, new antiretroviral drugs and classes have become available, and the prognosis of persons with HIV infection continues to improve. However, with fewer complications and increased survival, HIV-infected persons are increasingly developing common health problems that also affect the general population. Some of these conditions may be related to HIV infection itself or its treatment. HIV-infected persons should be managed and monitored for all relevant age- and sex-specific health problems. New information based on publications from the period 2009–2013 has been incorporated into this document.

scholarly journals Executive Summary: Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

2014 ◽  
Vol 58 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Judith A. Aberg ◽  
Joel E. Gallant ◽  
Khalil G. Ghanem ◽  
Patricia Emmanuel ◽  
Barry S. Zingman ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Hiv Infection ◽  
Healthcare Providers ◽  
Health Problems ◽  
Antiretroviral Drugs ◽  
Executive Summary ◽  
New Information ◽  
Immunodeficiency Virus ◽  
Care Guidelines ◽  
Evidence Based Guidelines

Abstract Evidence-based guidelines for the management of persons infected with human immunodeficiency virus (HIV) were prepared by an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America. These updated guidelines replace those published in 2009. The guidelines are intended for use by healthcare providers who care for HIV-infected patients. Since 2009, new antiretroviral drugs and classes have become available, and the prognosis of persons with HIV infection continues to improve. However, with fewer complications and increased survival, HIV-infected persons are increasingly developing common health problems that also affect the general population. Some of these conditions may be related to HIV infection itself or its treatment. HIV-infected persons should be managed and monitored for all relevant age- and sex-specific health problems. New information based on publications from the period 2009–2013 has been incorporated into this document.

scholarly journals Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America

2007 ◽  
Vol 45 (7) ◽  
pp. 807-825 ◽  
Author(s):  
L. Joseph Wheat ◽  
Alison G. Freifeld ◽  
Martin B. Kleiman ◽  
John W. Baddley ◽  
David S. McKinsey ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Health Care Providers ◽  
Antifungal Agents ◽  
Treatment Guidelines ◽  
Immunosuppressive Treatment ◽  
Case Series ◽  
Previous Treatment ◽  
Care Providers ◽  
New Information ◽  
Evidence Based Guidelines

Abstract Evidence-based guidelines for the management of patients with histoplasmosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 30:688–95). The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. Since 2000, several new antifungal agents have become available, and clinical trials and case series have increased our understanding of the management of histoplasmosis. Advances in immunosuppressive treatment for inflammatory disorders have created new questions about the approach to prevention and treatment of histoplasmosis. New information, based on publications from the period 1999–2006, are incorporated into this guideline document. In addition, the panel added recommendations for management of histoplasmosis in children for those aspects that differ from aspects in adults.

scholarly journals Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America

2008 ◽  
Vol 46 (12) ◽  
pp. 1801-1812 ◽  
Author(s):  
Stanley W. Chapman ◽  
William E. Dismukes ◽  
Laurie A. Proia ◽  
Robert W. Bradsher ◽  
Peter G. Pappas ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Health Care Providers ◽  
Antifungal Agents ◽  
Expert Panel ◽  
Evidence Based ◽  
Care Providers ◽  
Management Guidelines ◽  
New Information ◽  
Immunosuppressed Patients ◽  
Evidence Based Guidelines

Abstract Evidence-based guidelines for the management of patients with blastomycosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous management guidelines published in the April 2000 issue of Clinical Infectious Diseases. The guidelines are intended for use by health care providers who care for patients who have blastomycosis. Since 2000, several new antifungal agents have become available, and blastomycosis has been noted more frequently among immunosuppressed patients. New information, based on publications between 2000 and 2006, is incorporated in this guideline document, and recommendations for treating children with blastomycosis have been noted.

scholarly journals Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid Sites

2000 ◽  
Vol 74 (22) ◽  
pp. 10269-10273 ◽  
Author(s):  
Andrew J. Leigh Brown ◽  
Heather M. Precious ◽  
Jeannette M. Whitcomb ◽  
Joseph K. Wong ◽  
Marlynne Quigg ◽  
...  
Keyword(s):  
Amino Acids ◽  
Human Immunodeficiency Virus ◽  
Amino Acid ◽  
Hiv Infection ◽  
Reverse Transcriptase ◽  
Acid Sites ◽  
Antiretroviral Drugs ◽  
In Vitro Mutagenesis ◽  
Immunodeficiency Virus

ABSTRACT Recently, significant numbers of individuals with primary human immunodeficiency virus (HIV) infection have been found to harbor viral strains with reduced susceptibility to antiretroviral drugs. In one study, HIV from 16% of such antiretroviral-naive individuals was shown to have a susceptibility to nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) between 2.5- and 10-fold lower than that of a wild-type control. Mutations in the RT domain that had previously been associated with antiretroviral resistance were not shared by these strains. We have analyzed by logistic regression 46 variable amino acid sites in RT for their effect on susceptibility and have identified two novel sites influencing susceptibility to NNRTIs: amino acids 135 and 283 in RT. Eight different combinations of amino acids at these sites were observed among these patients. These combinations showed a 14-fold range in mean susceptibility to both nevirapine and delavirdine. In vitro mutagenesis of the control strain combined with a phenotypic assay confirmed the significance of amino acid variation at these sites for susceptibility to NNRTIs.

scholarly journals A Case of Oral Histoplasmosis Concomitant with Pulmonary Tuberculosis

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Silas Antonio Juvencio de Freitas Filho ◽  
Natália Galvão Garcia ◽  
Mário César de Souza ◽  
Denise Tostes Oliveira
Keyword(s):  
Human Immunodeficiency Virus ◽  
Pulmonary Tuberculosis ◽  
Infectious Diseases ◽  
Hiv Infection ◽  
Immunodeficiency Virus

The superficial intraoral lesions of histoplasmosis occurring concomitant to tuberculosis, in a 46-year-old man, are reported. The human immunodeficiency virus (HIV) infection test was negative. The immunosuppression caused by tuberculosis in our patient probably had an important role in the development of intraoral lesions of histoplasmosis. Here, we discussed the role of the dentist in the diagnosis of these infectious diseases, highlighting the importance of anamnesis and the histopathology/immunohistochemistry exams.

scholarly journals Complementary Antiviral Efficacy of Hydroxyurea and Protease Inhibitors in Human Immunodeficiency Virus-Infected Dendritic Cells and Lymphocytes

2002 ◽  
Vol 76 (5) ◽  
pp. 2274-2278 ◽  
Author(s):  
Giampiero Piccinini ◽  
Andrea Foli ◽  
Giuditta Comolli ◽  
Julianna Lisziewicz ◽  
Franco Lori
Keyword(s):  
Human Immunodeficiency Virus ◽  
T Cells ◽  
Dendritic Cells ◽  
Hiv Infection ◽  
Protease Inhibitors ◽  
Virus Production ◽  
Antiretroviral Drugs ◽  
Activated Lymphocytes ◽  
Immunodeficiency Virus

ABSTRACT Dendritic cells are susceptible to human immunodeficiency virus (HIV) infection and may transmit the virus to T cells in vivo. Scarce information is available about drug efficacy in dendritic cells because preclinical testing of antiretroviral drugs has been limited predominantly to T cells and macrophages. We compared the antiviral activities of hydroxyurea and two protease inhibitors (indinavir and ritonavir) in monocyte-derived dendritic cells and in lymphocytes. At therapeutic concentrations (50 to 100 μM), hydroxyurea inhibited supernatant virus production from monocyte-derived dendritic cells in vitro but the drug was ineffective in activated lymphocytes. Concentrations of hydroxyurea insufficient to be effective in activated lymphocytes cultured alone strongly inhibited supernatant virus production from cocultures of uninfected, activated lymphocytes with previously infected monocyte-derived dendritic cells in vitro. In contrast, protease inhibitors were up to 30-fold less efficient in dendritic cells than in activated lymphocytes. Our data support the rationale for testing of the combination of hydroxyurea and protease inhibitors, since these drugs may have complementary antiviral efficacies in different cell compartments. A new criterion for combining drugs for the treatment of HIV infection could be to include at least one drug that selectively targets HIV in viral reservoirs.

scholarly journals Medical and Islamic Perspectives on Human Immunodeficiency Virus Infection and its Prevention

2020 ◽  
Vol 18 (2) ◽  
Author(s):  
Abdullah F ◽  
Hashi AA ◽  
Said AH ◽  
Mat Nor MB
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hiv Infection ◽  
Healthcare Providers ◽  
Immune Deficiency Syndrome ◽  
Epidemiological Data ◽  
Deficiency Syndrome ◽  
People Living With Hiv ◽  
Immunodeficiency Virus ◽  
Living With Hiv ◽  
Hiv Aids

Human Immunodeficiency Virus (HIV) that causes Acquired Immune Deficiency Syndrome (AIDS) is one of the world’s most serious health and nation-state destructions. It creates long-term economic and psychosocial impact on the lives of individuals, families and communities. Since the first reported case of HIV/AIDS in Malaysia in 1986, its prevalence has escalated significantly. As of December 2017, there are over 115,263 reported cases of HIV infections in the country and over 40,000 people died from HIV/AIDS.1 Although many religious people regarded HIV infection as a divine punishment for their sins of sexual promiscuity, Islamic teaching emphasises the prevention of the disease and care for people living with HIV or AIDS. It is imperative to discuss the Islamic perspectives in providing ways to prevent the spread of HIV and support to people living with HIV (PLHIV). This article focuses on epidemiological data; highlight the burden of HIV infection/AIDS in Malaysia and its impact on the society, HIV infection from medical perspective and its preventive measures from Islamic viewpoints. A good teamwork among healthcare providers and religious leaders is compulsory as it may improve the preventive strategies to curb the disease in the country.

scholarly journals HIV and the Law: Integrating Law, Policy, and Social Epidemiology

2002 ◽  
Vol 30 (4) ◽  
pp. 533-547 ◽  
Author(s):  
Zita Lazzarini ◽  
Robert Klitzman
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hiv Infection ◽  
Social Epidemiology ◽  
Communicable Disease ◽  
Health Condition ◽  
Immunodeficiency Virus ◽  
The World ◽  
The Relationship ◽  
Specific Health Condition ◽  
Specific Health

In the foundational piece in this issue of the journal, “Integrating Law and Social Epidemiology,” Burris, Kawachi, and Sarat present a model for understanding the relationship between law and health. This article uses the case of a specific health condition, the human immunodeficiency virus (HIV) infection, as an opportunity to flesh out this schema and to test how the model “fits” the world of the HIV pandemic. In applying the model to this communicable disease, we hope to illustrate the multitude of ways that laws affect the course of the pandemic as well as the course of an individual’s vulnerability or resilience to the disease, and how the complexities of an individual’s life dealing with the virus interface with the world of laws and legal institutions.

Sign in / Sign up

Export Citation Format

Share Document